ADIL - EXCLUSIVE: Alcohol Disorder Focused Adial Pharmaceuticals Secures US Patent | Benzinga
On April 16, 2024, the United States Patent and Trademark Office issued patent number 11957664 to Adial Pharmaceuticals Inc (NASDAQ:ADIL).
This patent expands Adial’s intellectual property protection and covers the combination of the company’s proprietary genetic diagnostic to identify patients with specific genotypes for genetically targeted treatment of alcohol use disorder (AUD) and other drug dependencies, such as opioid use disorder (OUD), with the company’s lead investigational new drug product AD04.
Related: EXCLUSIVE: Adial Pharmaceuticals Announces New US Patent Covering ...